Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
39
BAYRY Quote, Financials, Valuation and Earnings
Last price:
$12.30
Seasonality move
:
3.55%
Day range:
$12.21 - $12.42
52-week range:
$5.30 - $14.85
Dividend yield:
0.25%
P/E ratio:
--
P/S ratio:
0.96x
P/B ratio:
1.39x
Volume:
1.6M
Avg. volume:
1.5M
1-year change:
103.81%
Market cap:
$48.4B
Revenue:
$50.4B
EPS (TTM):
-$0.09
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BAYRY
Bayer AG
|
$13.3B | $0.16 | 10.3% | 18.18% | $14.89 |
|
BNTX
BioNTech SE
|
$959.1M | -$0.10 | 95.94% | -30.65% | $139.12 |
|
IFRX
InflaRx NV
|
$30.9K | -$0.17 | -74.55% | -70.4% | $10.46 |
|
IMTX
Immatics NV
|
$10.9M | -$0.48 | -24.4% | -32.72% | $19.13 |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | -- |
|
MKKGY
Merck KGaA
|
$6.2B | $0.49 | 7.79% | 50.37% | $34.04 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BAYRY
Bayer AG
|
$12.31 | $14.89 | $48.4B | -- | $0.03 | 0.25% | 0.96x |
|
BNTX
BioNTech SE
|
$108.80 | $139.12 | $27.3B | 191.55x | $0.00 | 0% | 7.40x |
|
IFRX
InflaRx NV
|
$0.93 | $10.46 | $63.1M | -- | $0.00 | 0% | 287.62x |
|
IMTX
Immatics NV
|
$10.13 | $19.13 | $1.2B | 42.21x | $0.00 | 0% | 13.53x |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
MKKGY
Merck KGaA
|
$29.87 | $34.04 | $64.9B | 19.81x | $0.50 | 1.67% | 2.76x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BAYRY
Bayer AG
|
57.27% | -0.191 | 142.34% | 0.55x |
|
BNTX
BioNTech SE
|
1.31% | 1.308 | 1.22% | 6.78x |
|
IFRX
InflaRx NV
|
2.1% | -0.262 | 1.26% | 2.34x |
|
IMTX
Immatics NV
|
3.78% | 2.067 | 1.86% | 6.97x |
|
MDGEF
Medigene AG
|
-- | 0.000 | -- | -- |
|
MKKGY
Merck KGaA
|
29.49% | -0.053 | 25.12% | 0.76x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BAYRY
Bayer AG
|
$6.3B | $655.6M | -0.4% | -0.91% | 5.81% | $616.1M |
|
BNTX
BioNTech SE
|
$1.6B | $743.4M | -2.96% | -3.01% | 41.89% | $785.5M |
|
IFRX
InflaRx NV
|
-$89.2K | -$11.7M | -80.95% | -82.01% | -42057.91% | -$11.4M |
|
IMTX
Immatics NV
|
-- | -$63.9M | -24.18% | -25.21% | -1053.82% | -$56.2M |
|
MDGEF
Medigene AG
|
-- | -- | -- | -- | -- | -- |
|
MKKGY
Merck KGaA
|
$3.8B | $1.4B | 7.45% | 10.11% | 22.9% | $579.8M |
Bayer AG vs. Competitors
-
Which has Higher Returns BAYRY or BNTX?
BioNTech SE has a net margin of -9.93% compared to Bayer AG's net margin of -1.89%. Bayer AG's return on equity of -0.91% beat BioNTech SE's return on equity of -3.01%.
Company Gross Margin Earnings Per Share Invested Capital BAYRYBayer AG55.41% -$0.29 $81.5B BNTXBioNTech SE90.24% -$0.14 $22B -
What do Analysts Say About BAYRY or BNTX?
Bayer AG has a consensus price target of $14.89, signalling upside risk potential of 20.94%. On the other hand BioNTech SE has an analysts' consensus of $139.12 which suggests that it could grow by 27.87%. Given that BioNTech SE has higher upside potential than Bayer AG, analysts believe BioNTech SE is more attractive than Bayer AG.
Company Buy Ratings Hold Ratings Sell Ratings BAYRYBayer AG1 2 0 BNTXBioNTech SE14 5 0 -
Is BAYRY or BNTX More Risky?
Bayer AG has a beta of 0.677, which suggesting that the stock is 32.328% less volatile than S&P 500. In comparison BioNTech SE has a beta of 1.488, suggesting its more volatile than the S&P 500 by 48.755%.
-
Which is a Better Dividend Stock BAYRY or BNTX?
Bayer AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.25%. BioNTech SE offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bayer AG pays 4.24% of its earnings as a dividend. BioNTech SE pays out -- of its earnings as a dividend. Bayer AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BAYRY or BNTX?
Bayer AG quarterly revenues are $11.3B, which are larger than BioNTech SE quarterly revenues of $1.8B. Bayer AG's net income of -$1.1B is lower than BioNTech SE's net income of -$33.5M. Notably, Bayer AG's price-to-earnings ratio is -- while BioNTech SE's PE ratio is 191.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 0.96x versus 7.40x for BioNTech SE. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BAYRYBayer AG0.96x -- $11.3B -$1.1B BNTXBioNTech SE7.40x 191.55x $1.8B -$33.5M
-
Which has Higher Returns BAYRY or IFRX?
InflaRx NV has a net margin of -9.93% compared to Bayer AG's net margin of -51538.49%. Bayer AG's return on equity of -0.91% beat InflaRx NV's return on equity of -82.01%.
Company Gross Margin Earnings Per Share Invested Capital BAYRYBayer AG55.41% -$0.29 $81.5B IFRXInflaRx NV-320.86% -$0.21 $54.4M -
What do Analysts Say About BAYRY or IFRX?
Bayer AG has a consensus price target of $14.89, signalling upside risk potential of 20.94%. On the other hand InflaRx NV has an analysts' consensus of $10.46 which suggests that it could grow by 1022.95%. Given that InflaRx NV has higher upside potential than Bayer AG, analysts believe InflaRx NV is more attractive than Bayer AG.
Company Buy Ratings Hold Ratings Sell Ratings BAYRYBayer AG1 2 0 IFRXInflaRx NV5 2 0 -
Is BAYRY or IFRX More Risky?
Bayer AG has a beta of 0.677, which suggesting that the stock is 32.328% less volatile than S&P 500. In comparison InflaRx NV has a beta of 1.457, suggesting its more volatile than the S&P 500 by 45.659%.
-
Which is a Better Dividend Stock BAYRY or IFRX?
Bayer AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.25%. InflaRx NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bayer AG pays 4.24% of its earnings as a dividend. InflaRx NV pays out -- of its earnings as a dividend. Bayer AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BAYRY or IFRX?
Bayer AG quarterly revenues are $11.3B, which are larger than InflaRx NV quarterly revenues of $27.8K. Bayer AG's net income of -$1.1B is lower than InflaRx NV's net income of -$14.3M. Notably, Bayer AG's price-to-earnings ratio is -- while InflaRx NV's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 0.96x versus 287.62x for InflaRx NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BAYRYBayer AG0.96x -- $11.3B -$1.1B IFRXInflaRx NV287.62x -- $27.8K -$14.3M
-
Which has Higher Returns BAYRY or IMTX?
Immatics NV has a net margin of -9.93% compared to Bayer AG's net margin of -974.45%. Bayer AG's return on equity of -0.91% beat Immatics NV's return on equity of -25.21%.
Company Gross Margin Earnings Per Share Invested Capital BAYRYBayer AG55.41% -$0.29 $81.5B IMTXImmatics NV-- -$0.49 $508.8M -
What do Analysts Say About BAYRY or IMTX?
Bayer AG has a consensus price target of $14.89, signalling upside risk potential of 20.94%. On the other hand Immatics NV has an analysts' consensus of $19.13 which suggests that it could grow by 91.26%. Given that Immatics NV has higher upside potential than Bayer AG, analysts believe Immatics NV is more attractive than Bayer AG.
Company Buy Ratings Hold Ratings Sell Ratings BAYRYBayer AG1 2 0 IMTXImmatics NV9 0 0 -
Is BAYRY or IMTX More Risky?
Bayer AG has a beta of 0.677, which suggesting that the stock is 32.328% less volatile than S&P 500. In comparison Immatics NV has a beta of 1.359, suggesting its more volatile than the S&P 500 by 35.865%.
-
Which is a Better Dividend Stock BAYRY or IMTX?
Bayer AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.25%. Immatics NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bayer AG pays 4.24% of its earnings as a dividend. Immatics NV pays out -- of its earnings as a dividend. Bayer AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BAYRY or IMTX?
Bayer AG quarterly revenues are $11.3B, which are larger than Immatics NV quarterly revenues of $6.1M. Bayer AG's net income of -$1.1B is lower than Immatics NV's net income of -$59.1M. Notably, Bayer AG's price-to-earnings ratio is -- while Immatics NV's PE ratio is 42.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 0.96x versus 13.53x for Immatics NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BAYRYBayer AG0.96x -- $11.3B -$1.1B IMTXImmatics NV13.53x 42.21x $6.1M -$59.1M
-
Which has Higher Returns BAYRY or MDGEF?
Medigene AG has a net margin of -9.93% compared to Bayer AG's net margin of --. Bayer AG's return on equity of -0.91% beat Medigene AG's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BAYRYBayer AG55.41% -$0.29 $81.5B MDGEFMedigene AG-- -- -- -
What do Analysts Say About BAYRY or MDGEF?
Bayer AG has a consensus price target of $14.89, signalling upside risk potential of 20.94%. On the other hand Medigene AG has an analysts' consensus of -- which suggests that it could fall by --. Given that Bayer AG has higher upside potential than Medigene AG, analysts believe Bayer AG is more attractive than Medigene AG.
Company Buy Ratings Hold Ratings Sell Ratings BAYRYBayer AG1 2 0 MDGEFMedigene AG0 0 0 -
Is BAYRY or MDGEF More Risky?
Bayer AG has a beta of 0.677, which suggesting that the stock is 32.328% less volatile than S&P 500. In comparison Medigene AG has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock BAYRY or MDGEF?
Bayer AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.25%. Medigene AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bayer AG pays 4.24% of its earnings as a dividend. Medigene AG pays out -- of its earnings as a dividend. Bayer AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BAYRY or MDGEF?
Bayer AG quarterly revenues are $11.3B, which are larger than Medigene AG quarterly revenues of --. Bayer AG's net income of -$1.1B is higher than Medigene AG's net income of --. Notably, Bayer AG's price-to-earnings ratio is -- while Medigene AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 0.96x versus -- for Medigene AG. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BAYRYBayer AG0.96x -- $11.3B -$1.1B MDGEFMedigene AG-- -- -- --
-
Which has Higher Returns BAYRY or MKKGY?
Merck KGaA has a net margin of -9.93% compared to Bayer AG's net margin of 16.89%. Bayer AG's return on equity of -0.91% beat Merck KGaA's return on equity of 10.11%.
Company Gross Margin Earnings Per Share Invested Capital BAYRYBayer AG55.41% -$0.29 $81.5B MKKGYMerck KGaA60.42% $0.48 $48.3B -
What do Analysts Say About BAYRY or MKKGY?
Bayer AG has a consensus price target of $14.89, signalling upside risk potential of 20.94%. On the other hand Merck KGaA has an analysts' consensus of $34.04 which suggests that it could grow by 13.96%. Given that Bayer AG has higher upside potential than Merck KGaA, analysts believe Bayer AG is more attractive than Merck KGaA.
Company Buy Ratings Hold Ratings Sell Ratings BAYRYBayer AG1 2 0 MKKGYMerck KGaA1 0 0 -
Is BAYRY or MKKGY More Risky?
Bayer AG has a beta of 0.677, which suggesting that the stock is 32.328% less volatile than S&P 500. In comparison Merck KGaA has a beta of 0.973, suggesting its less volatile than the S&P 500 by 2.665%.
-
Which is a Better Dividend Stock BAYRY or MKKGY?
Bayer AG has a quarterly dividend of $0.03 per share corresponding to a yield of 0.25%. Merck KGaA offers a yield of 1.67% to investors and pays a quarterly dividend of $0.50 per share. Bayer AG pays 4.24% of its earnings as a dividend. Merck KGaA pays out 24.48% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BAYRY or MKKGY?
Bayer AG quarterly revenues are $11.3B, which are larger than Merck KGaA quarterly revenues of $6.2B. Bayer AG's net income of -$1.1B is lower than Merck KGaA's net income of $1B. Notably, Bayer AG's price-to-earnings ratio is -- while Merck KGaA's PE ratio is 19.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bayer AG is 0.96x versus 2.76x for Merck KGaA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BAYRYBayer AG0.96x -- $11.3B -$1.1B MKKGYMerck KGaA2.76x 19.81x $6.2B $1B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 13.92% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 5.87% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 4.76% over the past day.
